Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.
Neutralizing antibodies (NAb) able to react to heterologous viruses are generated during natural HIV-1 infection in some individuals. Further knowledge is required in order to understand the factors contributing to induction of cross-reactive NAb responses. Here a well-established model of experimental pathogenic infection in cynomolgus macaques, which reproduces long-lasting HIV-1 infection, was used to study the NAb response as well as the viral evolution of the highly neutralization-resistant SIVmac239. Twelve animals were infected intravenously with SIVmac239. Antiretroviral therapy (ART) was initiated ten days post-inoculation and administered daily for four months. Viral load, CD4(+) T-cell counts, total IgG levels, and breadth as well as strength of NAb in plasma were compared simultaneously over 14 months. In addition, envs from plasma samples were sequenced at three time points in all animals in order to assess viral evolution. We report here that seven of the 12 animals controlled viremia to below 10(4) copies/ml of plasma after discontinuation of ART and that this control was associated with a low level of evolutionary divergence. Macaques that controlled viral load developed broader NAb responses early on. Furthermore, escape mutations, such as V67M and R751G, were identified in virus sequenced from all animals with uncontrolled viremia. Bayesian estimation of ancestral population genetic diversity (PGD) showed an increase in this value in non-controlling or transient-controlling animals during the first 5.5 months of infection, in contrast to virus-controlling animals. Similarly, non- or transient controllers displayed more positively-selected amino-acid substitutions. An early increase in PGD, resulting in the generation of positively-selected amino-acid substitutions, greater divergence and relative high viral load after ART withdrawal, may have contributed to the generation of potent NAb in several animals after SIVmac239 infection. However, early broad NAb responses correlated with relatively preserved CD4(+) T-cell numbers, low viral load and limited viral divergence.
Ozkaya Sahin
Gülşen
G
Department of Laboratory Medicine, Lund University, Lund, Sweden.
Bowles
Emma J
EJ
Parker
Joe
J
Uchtenhagen
Hannes
H
Sheik-Khalil
Enas
E
Taylor
Stephen
S
Pybus
Oliver G
OG
Mäkitalo
Barbro
B
Walther-Jallow
Lilian
L
Spångberg
Mats
M
Thorstensson
Rigmor
R
Achour
Adnane
A
Fenyö
Eva Maria
EM
Stewart-Jones
Guillaume B E
GB
Spetz
Anna-Lena
AL
D019943:Amino Acid Substitution; D000818:Animals; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000627:therapeutic use*; D005075:Biological Evolution; D014644:Genetic Variation; D007074:Immunoglobulin G / Q000097:blood; D008252:Macaca fascicularis; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics; D009154:Mutation / Q000235:genetics; D010802:Phylogeny; D016133:Polymerase Chain Reaction; D012367:RNA, Viral; D016097:Simian Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D014759:Viral Envelope Proteins / Q000235:genetics; D019562:Viral Load / Q000187:drug effects / Q000276:immunology; D014766:Viremia / Q000188:drug therapy* / Q000276:immunology
D044966:Anti-Retroviral Agents; D057134:Antibodies, Neutralizing; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D012367:RNA, Viral; D014759:Viral Envelope Proteins; C069623:gp120 protein, Simian immunodeficiency virus
J Virol. 2009 Jul;83(14):7337-48
19439467
J Infect Dis. 1999 Jun;179(6):1365-74
10228056
J Virol. 1999 Mar;73(3):2343-9
9971817
J Virol. 1999 Sep;73(9):7795-804
10438870
J Virol. 2007 Dec;81(24):13456-68
17913797
J Virol. 1999 Dec;73(12):10489-502
10559367
AIDS Res Hum Retroviruses. 2006 Sep;22(9):917-23
16989619
J Virol. 1999 May;73(5):4009-18
10196297
Nature. 1991 Aug 1;352(6334):436-8
1677743
Annu Rev Med. 2007;58:461-76
17217334
Lancet. 1995 Aug 5;346(8971):372-3
7677904
Virology. 1993 Dec;197(2):609-15
7902628
J Gen Virol. 2005 Dec;86(Pt 12):3385-3396
16298986
J Virol. 1992 Apr;66(4):2067-75
1548752
Nat Med. 2000 Feb;6(2):200-6
10655110
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
Clin Exp Immunol. 2008 Oct;154(1):6-14
18761662
PLoS Biol. 2006 May;4(5):e88
16683862
Proc Natl Acad Sci U S A. 1986 Jul;83(14):5286-90
3014542
J Virol. 2009 Jan;83(2):757-69
18987148
J Virol. 2003 Mar;77(5):3119-30
12584337
Mol Biol Evol. 2005 Apr;22(4):942-51
15635055
AIDS. 1990 Feb;4(2):107-12
2328092
Vaccine. 2008 Jun 6;26(24):3016-25
18164520
AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):957-67
12230938
Curr Protoc Bioinformatics. 2003 Feb;Chapter 6:Unit 6.5
18428705
Mol Biol Evol. 1988 Nov;5(6):645-59
2464734
Nature. 1998 Jun 18;393(6686):705-11
9641684
N Engl J Med. 1995 Jan 26;332(4):201-8
7808485
Glycobiology. 2004 Dec;14(12):1229-46
15175256
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3392-6
1849654
J Virol. 2010 Feb;84(3):1302-13
19906907
Nature. 2005 Apr 28;434(7037):1093-7
15793563
AIDS. 1991 Jan;5(1):21-8
2059358
J Virol. 2007 Jun;81(12):6402-11
17392364
BMC Evol Biol. 2007 Nov 08;7:214
17996036
J Virol. 2001 Sep;75(17):8340-7
11483779
J Virol. 1996 Jan;70(1):427-44
8523556
J Virol. 2008 Aug;82(16):7932-41
18524815
J Virol. 1997 Oct;71(10):7518-25
9311831
Virol J. 2005 May 12;2:44
15890081
J Gen Virol. 2006 Mar;87(Pt 3):595-606
16476980
Syst Biol. 2003 Oct;52(5):696-704
14530136
Bioinformatics. 2006 Jan 15;22(2):195-201
16301204
J Infect Dis. 1997 Nov;176(5):1180-7
9359717
Bioinformatics. 1998;14(9):817-8
9918953
J Virol. 1997 May;71(5):3734-41
9094648
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
15572765
J Virol. 1997 Jul;71(7):5069-79
9188572
J Virol. 2007 Nov;81(21):11658-68
17699568
Nature. 2003 Mar 20;422(6929):307-12
12646921
J Virol. 2002 Mar;76(5):2123-30
11836389
Science. 1995 Jan 27;267(5197):483-9
7824947
PLoS Pathog. 2009 Sep;5(9):e1000594
19763269
Nat Med. 2009 Aug;15(8):866-70
19525964
Virology. 2000 Jul 20;273(1):52-9
10891407
AIDS. 1991 Oct;5(10):1173-8
1786144
J Virol. 2008 Oct;82(19):9739-52
18667507
Nat Med. 2000 Feb;6(2):207-10
10655111
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W700-3
16845102
Bioinformatics. 2005 Mar 1;21(5):676-9
15509596
J Virol. 1995 May;69(5):2737-44
7707496
Nat Rev Genet. 2004 Jan;5(1):52-61
14708016
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
15034147
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7
10737796
J Virol. 2009 Jan;83(1):188-99
18922865
J Virol. 2008 Dec;82(23):11651-68
18815292
Nat Med. 2009 Aug;15(8):951-4
19525965
Nat Med. 1999 Feb;5(2):204-10
9930869